Latest news

• FDA green light for Pfizer's eczema drug

  Pfizer's blockbuster-in-waiting Eucrisa has been approved by the FDA for eczema, becoming the first non-steroidal therapy for the skin condition in more than 15 years.

• Pfizer adds eczema drug with $5.2bn Anacor acquisition

  Pfizer adds eczema drug with $5.2bn Anacor acquisition. Expands innovative products business with non-steroidal therapy Crisaborole. ... and if approved would be the first new non-steroidal therapy for the skin condition in more than 15 years.

• Novartis wins childhood arthritis indication for Ilaris in EU

  Ilaris gains a new indication as a monthly subcutaneous injection in patients aged two years and older who have not responded to therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and ... The approval] represents another significant milestone in